Literature DB >> 2969267

Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors.

A Butler1, J M Hill, S J Ireland, C C Jordan, M B Tyers.   

Abstract

1. This paper describes the pharmacology of the novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist GR38032F. 2. On the isolated vagus nerve and superior cervical ganglion of the rat, R,S-GR38032F behaved as a reversible competitive antagonist of 5-HT-induced depolarization with pKB values of 8.61 +/- 0.08 (n = 19) and 8.13 +/- 0.07 (n = 16), respectively. The resolved R- and S-isomers of GR38032F were approximately equipotent as 5-HT antagonists on the rat vagus nerve: the pKB values were 8.95 +/- 0.05 (n = 16) and 8.63 +/- 0.08 (n = 17), respectively. R,S-GR38032F was also an effective antagonist of 5-HT on the rabbit isolated vagus nerve: in this case the pKB value was 9.40 +/- 0.14 (n = 4). 3. On the rabbit isolated heart, low concentrations of R,S-GR38032F (3 X 10(-11)-1 X 10(-9) M) antagonized the positive chronotropic effect of 5-HT and 2-methyl-5-hydroxytryptamine (2-methyl-5-HT). However, the effects of the compound did not appear consistent with simple reversible competition. 4. On the longitudinal smooth muscle of the guinea-pig ileum, R,S-GR38032F caused concentration-dependent parallel rightward displacement of the 2-methyl-5-HT concentration-contraction response curve; in contrast, a portion of the response to 5-HT appeared resistant to R,S-GR38032F. pKB values estimated from the effects of the compound against 2-methyl-5-HT or the inhibitable portion of the response to 5-HT were 7.31 +/- 0.06 (n = 8) and 7.33 +/- 0.13 (n = 8), respectively. Against 2-methyl-5-HT, R-GR38032F seemed more potent (pKB 7.20 +/- 0.10; n = 6) than S-GR38032F (pKB 6.30 +/- 0.05; n = 6). 5. R,S-GR38032F is highly selective for 5-HT3 receptors, and at concentrations of 3 X 10(-6)-3 X 10(-5) M, had negligible agonist or antagonist activity on other 5-HT or non-5-HT receptor-containing tissues on which it was tested. 6. The potency and duration of action of R,S-GR38032F in blocking 5-HT3 receptors in vivo were assessed by measuring its ability to antagonize the bradycardic response to 5-HT or 2-methyl-5-HT administered intravenously (i.v.) to anaesthetized animals. For i.v. administration to the rat, the ED50 for R,S-GR38032F against 2-methyl-5-HT (100pgkg-1) was 0.4 (95% confidence limits 0.18- 0.87) ygkg-1 (n = 10); the corresponding value for oral administration to this species was 7.0 (3.0- 22.0)pgkg-' (n = 8-10 per dose level). R,S-GR38032F was similarly effective in the anaesthetized cat. 7. The present results are discussed with reference to the postulated existence of subtypes of the 5-HT3 receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969267      PMCID: PMC1854010          DOI: 10.1111/j.1476-5381.1988.tb11542.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.

Authors:  P B Bradley; G Engel; W Feniuk; J R Fozard; P P Humphrey; D N Middlemiss; E J Mylecharane; B P Richardson; P R Saxena
Journal:  Neuropharmacology       Date:  1986-06       Impact factor: 5.250

2.  5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle.

Authors:  W Feniuk; P P Humphrey; A D Watts
Journal:  Eur J Pharmacol       Date:  1983-12-09       Impact factor: 4.432

3.  Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

Authors:  B P Richardson; G Engel; P Donatsch; P A Stadler
Journal:  Nature       Date:  1985 Jul 11-17       Impact factor: 49.962

4.  Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature.

Authors:  E Apperley; W Feniuk; P P Humphrey; G P Levy
Journal:  Br J Pharmacol       Date:  1980-02       Impact factor: 8.739

5.  The effects of alpha-adrenoceptor agonists and antagonists on responses of transmurally stimulated prostatic and epididymal portions of the isolated vas deferens of the rat.

Authors:  C M Brown; J C McGrath; R J Summers
Journal:  Br J Pharmacol       Date:  1979-08       Impact factor: 8.739

6.  Prenalterol is an agonist at beta 2- as well as at beta 1-adrenoceptors.

Authors:  G H Apperley; G M Drew; A T Sullivan
Journal:  Eur J Pharmacol       Date:  1982-07-30       Impact factor: 4.432

7.  Pharmacological evidence for the subclassification of central dopamine receptors in the rat.

Authors:  A J Gower; A S Marriott
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

8.  The depolarizing action of 5-hydroxytryptamine on rabbit vagal primary afferent and sympathetic neurones and its selective blockade by MDL 72222.

Authors:  J Azami; J R Fozard; A A Round; D I Wallis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

9.  MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.

Authors:  J R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

10.  The depolarizing action of 5-hydroxytryptamine on rabbit vagal afferent and sympathetic neurones in vitro and its selective blockade by ICS 205-930.

Authors:  A Round; D I Wallis
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

View more
  89 in total

1.  Intragastric capsaicin stimulates motility of upper gut and proximal colon via distinct pathways in conscious dogs.

Authors:  C Shibata; I Sasaki; H Naito; T Ueno; S Matsuno
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

2.  Pharmacological characterization of the 5-HT receptor-mediated contraction in the mouse isolated ileum.

Authors:  B R Tuladhar; M D Womack; R J Naylor
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Characterization of the 5-hydroxytryptamine receptors mediating contraction in the intestine of Suncus murinus.

Authors:  F A Javid; R J Naylor
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  Pharmacological characterization of 5-hydroxytryptamine-induced excitation of afferent cervical vagus nerve in anaesthetized rats.

Authors:  M Yoshioka; T Ikeda; M Abe; H Togashi; M Minami; H Saito
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

5.  Effect of the 5-HT3 receptor antagonists, MDL72222 and ondansetron on morphine place conditioning.

Authors:  G A Higgins; N Joharchi; P Nguyen; E M Sellers
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Identification and distribution of 5-HT3 recognition sites in the rat gastrointestinal tract.

Authors:  S Champaneria; B Costall; R J Naylor; D W Robertson
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

Review 7.  5-HT3 receptor antagonists and migraine therapy.

Authors:  M D Ferrari
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

8.  Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.

Authors:  E Vasar; E Peuranen; T Oöpik; J Harro; P T Männistö
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Further characterization of the putative 5-HT4 receptor mediating depolarization of the rat isolated vagus nerve.

Authors:  J Coleman; K F Rhodes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

10.  Characterization of 5-HT3 receptors of N1E-115 neuroblastoma cells by use of the influx of the organic cation [14C]-guanidinium.

Authors:  H Bönisch; M Barann; J Graupner; M Göthert
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.